• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program

    3/26/24 8:32:00 AM ET
    $CDXC
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $CDXC alert in real time by email

    All Tru Niagen products (except Tru Niagen 1,000mg, which is NSF Certified for Sport®) are Alkemist Assured

    ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces that its flagship Tru Niagen® product portfolio is now third-party verified through the Alkemist Assured™ testing transparency program by Alkemist Labs, a leading third-party testing laboratory known for its rigorous herbal and dietary supplement analysis. As the number one NAD+ supplement company in the US†, Tru Niagen features NIAGEN® (patented nicotinamide riboside or NR), the most efficient, patented, superior quality NAD+ precursor available on the market.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240326784617/en/

    All Tru Niagen products are Alkemist Assured except Tru Niagen PRO 1,000mg, which is NSF Certified for Sport®. (Photo: Business Wire)

    All Tru Niagen products are Alkemist Assured except Tru Niagen PRO 1,000mg, which is NSF Certified for Sport®. (Photo: Business Wire)

    The Alkemist Assured seal on Tru Niagen products provides consumers and stakeholders with an added layer of trust and confidence in the brand's commitment to excellence. Alkemist's verification process involves comprehensive testing of products for potency, identity, and purity, confirming they are free from contaminants and accurately labeled.

    "We hold Tru Niagen to the highest quality, safety, transparency, and scientific standards, and aligning with Alkemist Assured underscores our unwavering dedication to consumer trust," said Albert Rembart, VP of Product and Quality Safety at ChromaDex.

    Alkemist Labs is renowned for its state-of-the-art laboratory facilities and stringent testing methodologies. This program is expected to set a new industry standard for dietary supplement verification, offering unparalleled assurance of product identity, purity, and potency.

    "ChromaDex's decision to bring their Tru Niagen products into the Alkemist Assured program demonstrates their deep commitment to quality transparency," said Elan Sudberg, CEO of Alkemist Labs. "To add a company of ChromaDex's stature to the Alkemist Assured program is evidence that the nutraceuticals industry is stepping up to meet consumer's raised expectations."

    All Tru Niagen products are Alkemist Assured except Tru Niagen PRO 1,000mg, which is NSF Certified for Sport®. The entire product portfolio is also Star-K (Kosher), and IFANCA (Halal) certified.

    For more information about the quality behind Tru Niagen, please visit https://www.truniagen.com/quality/. To learn more about Alkemist Assured and their verification processes, visit https://www.alkemist.com/.

    †Based on the top-selling dietary supplement brands by revenue per the largest US e-commerce marketplace.

    About ChromaDex:

    ChromaDex Corp. (NASDAQ:CDXC) is the global authority on nicotinamide adenine dinucleotide (NAD+), with a focus on the science of healthy aging. The ChromaDex team, comprised of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to other everyday stressors. NAD+ depletion is a contributor to age-related changes in health and vitality. Setting the benchmark as the gold standard in scientific rigor, safety, quality, and transparency, ChromaDex is the innovator behind its clinically proven flagship ingredient, NIAGEN® (patented nicotinamide riboside, or NR), the most efficient and superior-quality NAD+ booster available.

    NIAGEN NR is the active ingredient in ChromaDex's consumer products, sold as the brand Tru Niagen®, the number one healthy-aging NAD+ supplement in the United States*. Clinically proven to increase NAD+ levels, Tru Niagen is helping people around the world transform the way they age (available at www.truniagen.com). ChromaDex's robust patent portfolio protects NR and other NAD+ precursors. ChromaDex maintains a website at www.chromadex.com, to which ChromaDex regularly publishes copies of its press releases, news, and financial information.

    *Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 3/1/2023-2/29/2024).

    About Alkemist Labs:

    Alkemist Labs is an ISO 17025 accredited contract testing laboratory specializing in plant authentication, botanical ingredient identification, quantitative analytical services and contaminant screening for the Food & Beverage, Nutraceutical and Cosmeceutical industries. Located in a state-of-the-art facility in Garden Grove, California, Alkemist Labs offers clients a wide range of specialty research services to evaluate the identity, purity, and quality of botanical raw materials, dietary ingredients, and finished products. DEA registered 1, 2, 3n, and 4 for over 20 years, Alkemist is also approved to be on California Department of Food and Agriculture (CDFA) list for hemp testing. Alkemist Labs also produces a complete line of Composite Reference Botanicals (CRBs), critical tools for botanical identity verification. Since it was founded in 1997, Alkemist Labs has become the ideal "Partner for Quality" to companies interested in producing high quality natural products requiring independent, third-party analysis, Stability/Shelf-life studies, Certification of Analysis, and cGMP compliance. https://www.alkemist.com/

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240326784617/en/

    Get the next $CDXC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CDXC

    DatePrice TargetRatingAnalyst
    8/16/2022Outperform → Perform
    Oppenheimer
    8/11/2022$6.00 → $2.40Buy → Neutral
    B. Riley Securities
    3/10/2022$16.00 → $8.00Buy
    B. Riley Securities
    3/8/2022$7.00Buy
    ROTH Capital
    8/4/2021$11.00 → $12.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CDXC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025

    ChromaDex Corp. (NASDAQ:CDXC), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it will change its corporate name to Niagen Bioscience, Inc. and trade under the new Nasdaq symbol "NAGE" effective at stock market open on Wednesday, March 19, 2025. As part of this transition, the Company will deploy a follow-up announcement with additional updates regarding the name change, rebrand, and future initiatives. No action is required by existing shareholders with respect to the ticker symbol change. The Company's common stock will continue to be listed on Nasdaq and the CUSIP will remain unchanged. For additional

    3/13/25 8:34:00 AM ET
    $CDXC
    Medicinal Chemicals and Botanical Products
    Health Care

    ChromaDex to Present at the 37th Annual Roth Conference

    ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science of healthy aging, today announces that senior management will participate at the 37th Annual ROTH Conference. ChromaDex CEO, Rob Fried, will participate on the Longevity and Supplementation Panel on Monday, March 17, at 12:00 PM PT (3:00 PM ET). Panels will be livestreamed and available at https://wsw.com/webcast/roth50. Additionally, ChromaDex's CEO, Rob Fried, and CFO, Ozan Pamir, will attend in-person one-on-one meetings with institutional investors throughout the day. This year's event will consist of one-on-one and small group meetings, analyst-selected fireside

    3/11/25 4:04:00 PM ET
    $CDXC
    Medicinal Chemicals and Botanical Products
    Health Care

    ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results

    Full year net sales of $99.6 million, up 19% from the prior year, gross margin of 61.8%, net income of $8.6 million, Adjusted EBITDA of $8.5 million, and $12.1 million in operating cash flows. Ended the year with $44.7 million in cash and no debt. Fourth quarter net sales of $29.1 million, up 37% from the prior year, gross margin of 62.5%, and net income of $7.2 million. ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2024 financial results. Fourth Quarter 2024 Total net sales of $29.1 million, with $22.7 million from Tru Niagen®, up 37% and 29%, respectively, from the prior year quarter. Posted strong gross margin of 62.5%, up 150 basis points from 61.0%

    3/4/25 4:02:00 PM ET
    $CDXC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CDXC
    SEC Filings

    View All

    ChromaDex Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Niagen Bioscience, Inc. (0001386570) (Filer)

    3/19/25 8:32:16 AM ET
    $CDXC
    Medicinal Chemicals and Botanical Products
    Health Care

    ChromaDex Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ChromaDex Corp. (0001386570) (Filer)

    3/4/25 4:02:10 PM ET
    $CDXC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-K filed by ChromaDex Corporation

    10-K - ChromaDex Corp. (0001386570) (Filer)

    3/4/25 4:01:06 PM ET
    $CDXC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CDXC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ChromaDex downgraded by Oppenheimer

    Oppenheimer downgraded ChromaDex from Outperform to Perform

    8/16/22 7:48:02 AM ET
    $CDXC
    Medicinal Chemicals and Botanical Products
    Health Care

    ChromaDex downgraded by B. Riley Securities with a new price target

    B. Riley Securities downgraded ChromaDex from Buy to Neutral and set a new price target of $2.40 from $6.00 previously

    8/11/22 7:50:39 AM ET
    $CDXC
    Medicinal Chemicals and Botanical Products
    Health Care

    B. Riley Securities reiterated coverage on ChromaDex with a new price target

    B. Riley Securities reiterated coverage of ChromaDex with a rating of Buy and set a new price target of $8.00 from $16.00 previously

    3/10/22 11:34:24 AM ET
    $CDXC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CDXC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, General Counsel Lopez Carlos Luis bought $2,146 worth of shares (273 units at $7.86), increasing direct ownership by 14% to 2,251 units (SEC Form 4)

    4 - ChromaDex Corp. (0001386570) (Issuer)

    3/10/25 8:11:11 AM ET
    $CDXC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 4 filed by Chief Executive Officer Fried Robert N

    4 - ChromaDex Corp. (0001386570) (Issuer)

    2/27/25 4:42:35 PM ET
    $CDXC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 4 filed by SVP, General Counsel Lopez Carlos Luis

    4 - ChromaDex Corp. (0001386570) (Issuer)

    2/14/25 6:19:33 PM ET
    $CDXC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CDXC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, General Counsel Lopez Carlos Luis bought $2,146 worth of shares (273 units at $7.86), increasing direct ownership by 14% to 2,251 units (SEC Form 4)

    4 - ChromaDex Corp. (0001386570) (Issuer)

    3/10/25 8:11:11 AM ET
    $CDXC
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Financial Officer Pamir Ozan bought $21,397 worth of shares (2,907 units at $7.36) (SEC Form 4)

    4 - ChromaDex Corp. (0001386570) (Issuer)

    11/25/24 7:28:56 AM ET
    $CDXC
    Medicinal Chemicals and Botanical Products
    Health Care

    Gerber Brianna bought $7,050 worth of shares (5,000 units at $1.41), increasing direct ownership by 22% to 27,436 units (SEC Form 4)

    4 - ChromaDex Corp. (0001386570) (Issuer)

    12/4/23 4:12:33 PM ET
    $CDXC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CDXC
    Leadership Updates

    Live Leadership Updates

    View All

    ChromaDex Appoints Ozan Pamir as Chief Financial Officer

    ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announces the appointment of Ozan Pamir as Chief Financial Officer. Mr. Pamir will oversee all ChromaDex corporate finance matters, including accounting, strategic financial planning, and engaging with public markets through investor relations. Effective October 21, 2024, he will report directly to Rob Fried, CEO of ChromaDex and Founder of Tru Niagen®. Mr. Fried commented, "We are very pleased to welcome Ozan to the ChromaDex team. His ambitious work ethic and impressive professional background will help us to embark on this critical next phase of develo

    9/20/24 8:32:00 AM ET
    $CDXC
    Medicinal Chemicals and Botanical Products
    Health Care

    ChromaDex Appoints Carlos Lopez as Senior Vice President, General Counsel

    ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announces the appointment of Carlos Lopez as Senior Vice President, General Counsel. Mr. Lopez will oversee the organization's legal function, including corporate governance, securities, intellectual property, and litigation. Effective today, July 22, 2024, he will report directly to Rob Fried, CEO of ChromaDex and Founder of Tru Niagen®. Carlos Lopez is a distinguished legal professional and executive leader with expertise in the dietary supplements industry. Prior to joining ChromaDex, he served as the Vice President, General Counsel at The Vitamin Sh

    7/22/24 8:34:00 AM ET
    $CDXC
    Medicinal Chemicals and Botanical Products
    Health Care

    ChromaDex to Join Russell 2000® Index

    ChromaDex continues to drive innovation and growth with its proprietary Tru Niagen® supplement, backed by strong financial performance and a robust intellectual property portfolio ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, today announced its inclusion in the Russell 2000® Index as part of the annual reconstitution of the Russell stock indexes. This inclusion will be effective at the opening of U.S. equity markets on Monday, July 1, 2024, based on the preliminary list of additions posted on Friday, May 24, 2024. Rob Fried, CEO of ChromaDex and Founder of Tru Niagen commented, "Joining the Russel

    7/1/24 8:32:00 AM ET
    $CDXC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CDXC
    Financials

    Live finance-specific insights

    View All

    ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results

    Full year net sales of $99.6 million, up 19% from the prior year, gross margin of 61.8%, net income of $8.6 million, Adjusted EBITDA of $8.5 million, and $12.1 million in operating cash flows. Ended the year with $44.7 million in cash and no debt. Fourth quarter net sales of $29.1 million, up 37% from the prior year, gross margin of 62.5%, and net income of $7.2 million. ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2024 financial results. Fourth Quarter 2024 Total net sales of $29.1 million, with $22.7 million from Tru Niagen®, up 37% and 29%, respectively, from the prior year quarter. Posted strong gross margin of 62.5%, up 150 basis points from 61.0%

    3/4/25 4:02:00 PM ET
    $CDXC
    Medicinal Chemicals and Botanical Products
    Health Care

    ChromaDex to Report Fourth Quarter and Fiscal Year 2024 Financial Results on Tuesday, March 4, 2025

    ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announces that it will hold a conference call on Tuesday, March 4, 2025, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and fiscal year 2024 financial results, which ended December 31, 2024. The financial results will be reported in a press release after the close of regular stock market trading hours on Tuesday, March 4, 2025. Investor Conference Call: ChromaDex management will host an investor conference call to discuss the fourth quarter and fiscal year 2024 results and provide a general business update on Tuesday, March 4, 2

    2/25/25 4:07:00 PM ET
    $CDXC
    Medicinal Chemicals and Botanical Products
    Health Care

    ChromaDex Corporation Reports Third Quarter 2024 Financial Results

    Total net sales of $25.6 million, up $6.1 million or 31% year-over-year, gross margin of 63.5% and record net income and adjusted EBITDA of $1.9 million and $2.9 million, respectively, for the three months ended September 30, 2024 ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the third quarter of 2024. Third Quarter 2024 Financial and Recent Operational Highlights Total net sales were $25.6 million, with $18.1 million from Tru Niagen®, up 31%, and 4%, respectively, from the prior year quarter. Total Niagen® ingredient sales, including food-grade and pharmaceutical-grade, reached $6.7 million, up 368% YoY. Delivered strong gross margin of 63.5%, up 210 basis poi

    10/31/24 4:04:00 PM ET
    $CDXC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CDXC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by ChromaDex Corporation

    SC 13D/A - ChromaDex Corp. (0001386570) (Subject)

    8/21/24 6:06:58 AM ET
    $CDXC
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SC 13D/A filed by ChromaDex Corporation

    SC 13D/A - ChromaDex Corp. (0001386570) (Subject)

    8/21/24 6:05:57 AM ET
    $CDXC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D/A filed by ChromaDex Corporation (Amendment)

    SC 13D/A - ChromaDex Corp. (0001386570) (Subject)

    9/7/23 6:20:26 AM ET
    $CDXC
    Medicinal Chemicals and Botanical Products
    Health Care